Krystal Biotech Q2 EPS Forecast Lowered by HC Wainwright

Krystal Biotech, Inc. (NASDAQ:KRYS) – Investment analysts at HC Wainwright lowered their Q2 2025 EPS estimates for shares of Krystal Biotech in a research note issued on Tuesday, May 6th. HC Wainwright analyst J. Pantginis now expects that the company will earn $1.71 per share for the quarter, down from their previous forecast of $1.74. HC Wainwright currently has a “Buy” rating and a $240.00 target price on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is $6.14 per share. HC Wainwright also issued estimates for Krystal Biotech’s Q3 2025 earnings at $1.94 EPS.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.38 by ($0.18). Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The business had revenue of $88.18 million for the quarter, compared to analyst estimates of $98.66 million.

A number of other equities research analysts have also recently weighed in on the stock. Citigroup lifted their price target on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research report on Thursday, February 20th. Chardan Capital reissued a “buy” rating and issued a $219.00 target price on shares of Krystal Biotech in a research report on Wednesday. Jefferies Financial Group began coverage on Krystal Biotech in a research report on Wednesday, March 5th. They set a “buy” rating and a $245.00 price target for the company. Guggenheim cut their price objective on Krystal Biotech from $195.00 to $189.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 target price on shares of Krystal Biotech in a research note on Thursday, February 20th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $218.63.

Krystal Biotech Trading Down 3.6 %

Shares of NASDAQ:KRYS opened at $132.23 on Thursday. The company has a market capitalization of $3.82 billion, a price-to-earnings ratio of 44.22 and a beta of 0.79. Krystal Biotech has a 12-month low of $131.71 and a 12-month high of $219.34. The business has a 50-day moving average price of $171.56 and a 200 day moving average price of $170.06.

Insider Buying and Selling at Krystal Biotech

In related news, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the transaction, the chief accounting officer now owns 12,604 shares in the company, valued at $2,208,472.88. The trade was a 5.62 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the sale, the insider now directly owns 1,463,711 shares in the company, valued at approximately $260,233,178.69. This represents a 1.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 13.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Krystal Biotech

A number of institutional investors and hedge funds have recently modified their holdings of the company. Fifth Third Bancorp raised its stake in Krystal Biotech by 159.1% in the first quarter. Fifth Third Bancorp now owns 171 shares of the company’s stock valued at $31,000 after buying an additional 105 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in shares of Krystal Biotech during the 3rd quarter worth about $40,000. GF Fund Management CO. LTD. acquired a new stake in shares of Krystal Biotech during the 4th quarter worth about $95,000. GAMMA Investing LLC lifted its stake in Krystal Biotech by 179.3% during the first quarter. GAMMA Investing LLC now owns 673 shares of the company’s stock worth $121,000 after purchasing an additional 432 shares during the last quarter. Finally, Covestor Ltd boosted its holdings in Krystal Biotech by 972.7% in the fourth quarter. Covestor Ltd now owns 708 shares of the company’s stock valued at $111,000 after purchasing an additional 642 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).